Entresto
A pill used to treat certain types of chronic heart failure, when the heart cannot pump or fill with blood properly.
Cosentyx
An injection for inflammatory conditions including psoriasis, some forms of arthritis and a chronic skin disease called hidradenitis suppurativa.
Kisqali
A cancer medicine used with hormone treatment for certain types of breast cancer.
Kesimpta
A monthly self-injection for adults with relapsing forms of multiple sclerosis, a disease in which the immune system damages nerves.
Pluvicto
An intravenous treatment that delivers radioactive particles to certain prostate cancer cells.
Leqvio
An injection given by a health professional to lower low-density lipoprotein (LDL) cholesterol, a type of fat in the blood.
Novartis researches, tests, manufactures and sells prescription medicines in about 120 countries (2025, high). Its research focuses on heart, kidney and metabolic diseases, immune disorders, brain and nerve diseases, and cancer. Net sales were USD 54.532 billion (FY2025, high).
Costruito dai documenti depositati da Novartis AG presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
160,26 USD-0,1%chiusura 12 nov
Dati fino al 30 settembre 2026, dal 6-K depositato il 27 ottobre 2026
Novartis sells prescription medicines for heart disease, cancer and immune disorders to drug wholesalers, pharmacies, hospitals and health systems.
The themes Novartis is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade A
La fascia sotto il prezzo mostra il voto in ogni data, calcolato solo sui documenti già pubblici in quel momento.
Mostra 2 trimestri su 29 dello storico dei voti di Novartis AG. Gli altri 27 risalgono fino a gennaio 2018.